The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions

Jindan Li; Chaojiang Fu; Sheng Zhao; Yongzhu Pu; Fake Yang; Shuguang Zeng; Conghui Yang; Hongqiang Gao; Long Chen

doi:10.3389/fonc.2023.920896

The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions

Front Oncol. 2023 Apr 28:13:920896. doi: 10.3389/fonc.2023.920896. eCollection 2023.

Authors

Jindan Li¹, Chaojiang Fu², Sheng Zhao¹, Yongzhu Pu¹, Fake Yang¹, Shuguang Zeng³, Conghui Yang¹, Hongqiang Gao⁴, Long Chen¹

Affiliations

¹ Department of PET-CT/MR Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
² Department of Emergency, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan, China.
³ Department of Information Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical Cancer Center of Yunnan Province, Kunming, Yunnan, China.
⁴ Department of Hepatobiliary Surgery, The First People's Hospital of Kunming City & Ganmei Affiliated Hospital of Kunming Medical University, Kunming, China.

Abstract

Recently, the morbidity and mortality of pancreatic cancer have been increasing year by year. Because of its deep anatomical location and because most presented patients often suffer from abdominal pain or jaundice, it is difficult to diagnose pancreatic cancer at an early stage, leading to late clinical stage and poor prognosis. integrated positron emission tomography/magnetic resonance imaging (PET/MRI) fusion imaging not only has the characteristics of high resolution and multi-parameter imaging of MRI, but also combines the high sensitivity and the semi-quantitative characteristics of PET. In addition, the continuous development of novel MRI imaging and PET imaging biomarkers provide a unique and precise research direction for future pancreatic cancer research. This review summarizes the value of PET/MRI in the diagnosis, staging, efficacy monitoring, and prognosis evaluation of pancreatic cancer, and prognosis for developing emerging imaging agents and artificial intelligence radiomics in pancreatic cancer.

Keywords: PET/MRI; efficacy monitoring; emerging imaging agents; pancreatic cancer; prognosis evaluation.

Publication types

Review

Grants and funding

This study was supported by the National Natural Science Foundation of China (No. 81960496), Yunnan Fundamental Research Projects (No. 202101AT070050), Xing Dian Ying Cai Support Plan.